Education
About Us
Working with TipRanks
Follow Us
cbdMD (YCBD)
:YCBD
YCBD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.76 - $6.54
Previous CloseN/A
Volume938.08K
Average Volume (3M)72.14K
Market Cap
$7.66M
Enterprise Value$817.15K
Total Cash (Recent Filing)$1.77M
Total Debt (Recent Filing)$1.15M
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Aug 13, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding8,908,406
10 Day Avg. Volume75,035
30 Day Avg. Volume72,143
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.11
Enterprise Value/Revenue0.04
Enterprise Value/Gross Profit0.07
Enterprise Value/Ebitda0.58
Forecast
1Y Price Target
$3.00Price Target Upside248.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityThe successful conversion of Series A preferred stock into common equity is seen as a significant milestone, enhancing financial flexibility by eliminating all accrued and future dividend obligations.
Market ExpansionEngagement with national retailers and final stages of contract negotiations with multiple distributors are expected to position YCBD for category growth.
Product PortfolioThe early commercial traction of YCBD's Herbal Oasis line of THC-infused social tonics is encouraging, with initial sales recorded and expanded distribution into four states.
Bears Say
Compliance IssuesManagement received a notification of noncompliance with the NYSE's minimum shareholder's equity requirement.
Earnings PerformanceF2Q25 results fell short of expectations due to marketing inefficiencies and inventory shortages, creating temporary commercial bottlenecks.
Price Target ReductionDue to lower estimates and significant dilution related to the company's automatic preferred-to-common equity conversion, the price target is reduced to $3.00 from $16.00.
cbdMD News
YCBD FAQ
What was cbdMD’s price range in the past 12 months?
cbdMD lowest stock price was $0.76 and its highest was $6.54 in the past 12 months.
What is cbdMD’s market cap?
cbdMD’s market cap is $7.66M.
When is cbdMD’s upcoming earnings report date?
cbdMD’s upcoming earnings report date is Aug 13, 2025 which is in 9 days.
How were cbdMD’s earnings last quarter?
cbdMD released its earnings results on May 15, 2025. The company reported -$1.9 earnings per share for the quarter, missing the consensus estimate of -$1.6 by -$0.3.
Is cbdMD overvalued?
According to Wall Street analysts cbdMD’s price is currently Undervalued.
Does cbdMD pay dividends?
cbdMD does not currently pay dividends.
What is cbdMD’s EPS estimate?
cbdMD’s EPS estimate is -0.02.
How many shares outstanding does cbdMD have?
cbdMD has 8,908,406 shares outstanding.
What happened to cbdMD’s price movement after its last earnings report?
cbdMD reported an EPS of -$1.9 in its last earnings report, missing expectations of -$1.6. Following the earnings report the stock price went down -4.04%.
Which hedge fund is a major shareholder of cbdMD?
Currently, no hedge funds are holding shares in YCBD
Company Description
cbdMD
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. It also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. The company distributes its products through its e-commerce Website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. It has a research partnership with the University of Mississippi to identify novel cannabinoids. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.
YCBD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted substantial progress in capital restructuring and cost reduction, positioning the company well for future growth. However, challenges remain with flat e-commerce sales, a decrease in overall net sales, and a working capital deficit.Read More>YCBD Stock 12 Month Forecast
Average Price Target
$3.00
▲(248.84%Upside)
Technical Analysis
Tilray
―
Takeda Pharmaceutical Company
―
SNDL
―
Flora Growth
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
7.80% Insiders
0.11% Mutual Funds
2.10% Other Institutional Investors
89.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---